Merck & Co., Inc. (NYSE:MRK) Stock Acquired Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Merck & Co., Inc. (NYSE:MRK). In a filing disclosed on August 29th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on August 28th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of Southern (NYSE:SO) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of Novo Nordisk A/S (NYSE:NVO) on 8/28/2025.
• Purchased $15,001 – $50,000 in shares of Exelon (NASDAQ:EXC) on 8/28/2025.
• Purchased $15,001 – $50,000 in shares of Ryman Hospitality Properties (NYSE:RHP) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of MercadoLibre (NASDAQ:MELI) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 8/28/2025.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $84.13 on Tuesday. The firm has a market cap of $210.14 billion, a PE ratio of 12.96, a PEG ratio of 0.89 and a beta of 0.37. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $120.30. The company has a fifty day moving average price of $82.22 and a 200 day moving average price of $82.98.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Investors of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a yield of 3.9%. Merck & Co., Inc.’s dividend payout ratio is presently 49.92%.

Wall Street Analyst Weigh In

MRK has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 30th. Cantor Fitzgerald lowered shares of Merck & Co., Inc. from an “overweight” rating to a “cautious” rating in a research note on Tuesday, May 20th. Citigroup reaffirmed a “neutral” rating and issued a $84.00 target price (down from $115.00) on shares of Merck & Co., Inc. in a research note on Wednesday, May 14th. Finally, Morgan Stanley reduced their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $107.44.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of large investors have recently modified their holdings of MRK. DLD Asset Management LP bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $2,889,340,000. Norges Bank bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $2,858,570,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Merck & Co., Inc. by 144.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock valued at $4,418,820,000 after purchasing an additional 29,104,112 shares during the period. Nuveen LLC bought a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at about $991,553,000. Finally, Franklin Resources Inc. raised its holdings in shares of Merck & Co., Inc. by 23.5% in the 2nd quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock valued at $2,139,901,000 after purchasing an additional 5,135,748 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.